MESIS GENETICS: significantly improves the efficiency of current methods by implementing predictive and non-invasive tests.

Significantly improves the efficiency of current methods by implementing predictive and non-invasive tests.

CONTEXT
The success rate of medically assisted procreation is a relatively low 20% per attempt using traditional IVF (in vitro  fertilization) methods, or IVF/ICSI (Intra Cytoplasmic Sperm Injection). Despite the rising number of attempts, the success rate has remained stable for over 15 years. In order to improve the success rate, it is important to be able to control several parameters, such as the quality of the chosen spermatozoid, ovocyte, embryo, and patient’s endometrium.

Today’s predictive methods are mainly based on anatomical and observed criteria, and are thus subjective and operator-dependent.

The MESIS GENETICS project team has identified, on one hand, a molecular signature in cumulus cells whose expression predicts ovocyte quality; and on the other hand, a molecular gene signature that predicts the endometrium’s receptive quality. Leveraging these factors, the project team offers tests that make it possible to generate predictive and indicative data, and to make informed recommendations regarding the:

- Choice of embryo(s) to implant

- Endometrium receptivity

BENEFITS
These non-invasive tests make it possible to increase the chances of success significantly.

Using these tests, couples benefit from:

- A higher probability of pregnancy and birth of a child starting with the first attempt.

- A reduced incidence of multiple births.

- Highly improved quality of medical advice, including the option to recommend not to implant (and thus to freeze embryos) when the optimal implantation conditions are not satisfied.

APPLICATIONS
Medically assisted procreation (MAP), in vitro fertilization (IVF), micro-injection of spermatozoid into the ovocyte (Intra Cytoplasmic Sperm Injection – ICSI).